CHINO HILLS, CA / ACCESS Newswire / June 30, 2025 / SOHM, Inc. (OTC PINK:SHMN), a pharmaceutical and biotechnology firm recognized for its expertise in generic drugs, gene-editing technologies, and comprehensive health and wellness solutions, today announced a significant addition to its leadership. Mr. Ravi Kapoor has been appointed as an Independent Director to the SOHM Board, bringing over three decades of profound experience in corporate law, mergers and acquisitions (M&A), and financial management. His appointment is set to bolster the company’s strategic direction and governance, reinforcing SOHM’s commitment to robust corporate oversight and forward-thinking development.
Mr. Kapoor’s distinguished career includes his role as proprietor of Ravi Kapoor & Associates and a key partner at Yan Advisory Services LLP and Amity Consultants LLP. He is also a registered Insolvency Professional with the Insolvency & Bankruptcy Board of India, a testament to his dedication to the highest standards of corporate governance and ethical practice.
His extensive academic and professional qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, equip him with a nuanced understanding of complex corporate structures and operations. Mr. Kapoor has held critical positions as Company Secretary at several leading corporations, underscoring his practical acumen.
Furthermore, Mr. Kapoor has a proven track record of impactful board service, having contributed to the successes of prominent organizations such as Concord Biotech Limited and Sanghi Industries Limited, an Adani Group enterprise. His involvement at these entities was instrumental in driving innovation and fostering significant growth.
“I am honored and eager to join the Board of SOHM Inc. and lend my experience to its continued trajectory of success. I anticipate a collaborative effort with my fellow directors and the dedicated management team to identify and capitalize on new avenues of growth, ultimately enhancing shareholder value,” stated Mr. Kapoor.
“The onboarding of Mr. Kapoor marks a pivotal moment for SOHM as we advance our strategic initiatives. His sophisticated expertise will be paramount in catalyzing SOHM’s growth and expansion efforts,” commented David Aguilar, COO of SOHM.
SOHM Inc. is confident that Mr. Kapoor’s seasoned ability to navigate intricate corporate landscapes will provide invaluable insights as the company deepens its mission to deliver cutting-edge healthcare and biotechnological solutions that redefine patient care.
About SOHM, Inc.:
SOHM is a dynamic biopharmaceutical company committed to pioneering the development and commercialization of groundbreaking gene editing technologies. Its applications span critical areas such as research, synthetic biology, and therapeutic interventions. With a sharp focus on precision medicine, SOHM endeavors to revolutionize the treatment paradigm for genetic diseases, offering safe, efficient, and precisely targeted gene editing solutions. Through strategic alliances and relentless research, SOHM is actively shaping the future of gene therapy, aiming to transform the landscape of genome editing and elevate the quality of life through scientific breakthroughs.
This news release contains “forward-looking statements,” which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc.
View the original press release on ACCESS Newswire
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/3671.html
